ORIL is an Australian public, unlisted company with over 500 shareholders and approximately 42 million shares on issue. At the completion of Phase IB studies the company expects to be in a strong position to licensing the technology. ORIL also recognizes the need to be flexible and ready for negotiation at any time, should a partnering opportunity arise.
ORIL considers that the risks can be mitigated by good management of the science and R&D program entailing the knowledge and experience of the key personnel, and that the milestones are deliverable and achievable based on results achieved to date, and that the timings are reasonable subject to necessary funding.
Notwithstanding the company also recognises that historically the industry rate of success in developing new cancer drugs from discovery to market approval is around 4‑5%.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia